title: The structure-function relationship of GLP-1 related peptides in the endocrine function of the canine pancreas.
abstract: In order to clarify the relationship between the structure and function of glucagon-like peptide (GLP) 1 in the endocrine function of the pancreas, the response of insulin and glucagon to various synthetic GLP-1-related peptides was investigated in anesthetized dogs. GLP-1-related peptides were administered in a dosage of 400 pmol within 10 min into the pancreatic artery during glucose or arginine infusion and the changes in plasma insulin and glucagon in the pancreatic vein were studied. GLP-1 (7-36) and (7-37), as well as glucagon enhanced insulin release during glucose infusion, whereas neither GLP-1 (1-37), (7-20), (6-37) nor (8-37) stimulated insulin release. The administration of GLP-1 (1-37), (7-36) and (7-37) reduced glucagon release during glucose infusion. When arginine was infused, GLP-1 (7-20), (7-36), (7-37), and glucagon enhanced insulin release. In contrast, glucagon release was increased by the administration of GLP-1 (7-20), (8-37), and (7-37). The present study indicates that histidine at the 7th position of GLP-1 is important in eliciting biological action and that only truncated GLP-1 (7-36), (7-37), and (7-20) showed an insulinotropic action as strong as glucagon in dogs. Furthermore, it is suggested that the response of insulin and glucagon to GLP-1-related peptides is dependent on a background condition.
authors.affiliation: Health Center, Tohoku University, Sendai.
authors.forename: A
authors.initials: A
authors.lastname: Ohneda
authors.forename: K
authors.initials: K
authors.lastname: Ohneda
authors.forename: M
authors.initials: M
authors.lastname: Ohneda
authors.forename: F
authors.initials: F
authors.lastname: Koizumi
authors.forename: S
authors.initials: S
authors.lastname: Ohashi
authors.forename: K
authors.initials: K
authors.lastname: Kawai
authors.forename: S
authors.initials: S
authors.lastname: Suzuki
mesh_terms: D000818:Animals; D001285:Atropine / Q000008:administration & dosage; D004285:Dogs; D005934:Glucagon / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology*; D052216:Glucagon-Like Peptide 1; D004763:Glucagon-Like Peptides; D005947:Glucose / Q000008:administration & dosage; D007328:Insulin / Q000378:metabolism; D000078790:Insulin Secretion; D007515:Islets of Langerhans / Q000187:drug effects* / Q000378:metabolism; D010446:Peptide Fragments / Q000737:chemistry / Q000494:pharmacology*; D010455:Peptides / Q000494:pharmacology; D011498:Protein Precursors / Q000737:chemistry / Q000494:pharmacology*; D013329:Structure-Activity Relationship
chemical_list: D007328:Insulin; D010446:Peptide Fragments; D010455:Peptides; D011498:Protein Precursors; C061970:glucagon-like peptide 1 (7-36); D004763:Glucagon-Like Peptides; D001285:Atropine; C055968:glucagon-like peptide 1 (1-37); D052216:Glucagon-Like Peptide 1; D005934:Glucagon; D005947:Glucose; C051322:glucagon-like peptide 1 (7-37)